Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

Yes, metabolic dysfunction-associated steatohepatitis (MASH) can result in cirrhosis of the liver. Formerly known as nonalcoholic steatohepatitis (NASH), MASH describes a type of metabolic ...

Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

That was until my doctors stunned me with the news that I had cirrhosis caused by non-alcoholic steatohepatitis, or NASH, a severe form of fatty liver disease that often has few or no symptoms ...

Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a ...

If you have obesity, losing even a little weight helps not only improve your overall health, but also prevent liver issues ...

Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study offers one available option: bariatric surgery. Weight loss operations ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in ...

Nonalcoholic steatohepatitis (NASH) is a common disease that may progress to cirrhosis and liver failure. NASH is associated with overnutrition, obesity and insulin resistance. Genetic ...